Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INL1 (Trientine) in Heart Failure with Reduced Ejection Fraction
NCT03875183Phase 2Unknown
- Sponsor
- Innolife Co., Ltd.
- Start
- Jan 2020
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of trientine in heart failure with reduced ejection fraction (HFrEF), sponsored by Innolife Co., Ltd.. Status: unknown.
02
Drugs
trientine
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT03875183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03875183.